-transparent.png){kind=logo}
Monoclonal antibodies (McAbs), reactive with tumour-associated antigens (TAAs) present on tumour cells, appear to offer new possibilities in the diagnosis and treatment of cancer (Table I). In addition to these prospects for clinical application, monoclonal antibodies also serve as useful instruments in basic cancer research. The hybridoma technology initiated by Köhler and Milstein in 1975, underwent a very rapid development and has now shown its potential in the field of oncology. This technique made it possible to produce very large quantities of homogeneous antibodies of a stable quality. These McAbs often recognize only one antigenic determinant, or epitope, of cell surface and other molecules. This high specificity is essential for in vivo applications, especially in therapeutic immunotargeting. A central question is whether the antibodies can reach and identify those antigens on ovarian tumour cells that are not shared with normal tissues. Various antibodies have been described in the field of gynaecological oncology, which are assumed to be capable of recognizing such ovarian tumour-related antigens. These McAbs, single or in combination, are capable of showing, unambiguously, the presence of various tumour-associated antigens on ovarian carcinoma cells either in tissue or, when antigen shedding occurs, in blood. However, these McAbs may also react with tumour-associated antigens present on endometrial, cervical, colorectal, breast or other carcinoma cells. The original immunogens used to generate these McAbs differ as to their origin: ovarian cancer cells, breast cancer cells, human milk-fat preparations, trophoblastic cells, endometrial cancer cells have been used as well as osteogenic sarcoma cells, epidermoid carcinoma cells and small-cell lung cancer, colorectal, pancreatic and laryngeal carcinoma cells. The histological distribution patterns of the antigens recognized by these McAbs vary widely: cross-reactions with normal tissue and with carcinomas different from those used as immunogen are frequently seen.
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
October 1986,
Cancer research,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
January 1987,
Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
January 1987,
Progress in experimental tumor research,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
March 1988,
Human cell,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
December 1986,
Cancer research,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
January 1991,
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
January 1989,
Anticancer research,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
August 1990,
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
May 1986,
Journal of the National Cancer Institute,
P Kenemans, and
C A Yedema, and
J H Hilgers, and
L F Massuger, and
R H Verheijen, and
C M Thomas, and
L G Poels
August 1993,
Annals of the New York Academy of Sciences,
